IBRX Jan 2025 4.500 call
| Previous close | 2.0000 |
| Open | 2.0000 |
| Bid | 2.1500 |
| Ask | 2.4000 |
| Strike | 4.50 |
| Expiry date | 2025-01-17 |
| Day's range | 2.0000 - 2.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 167 |
Business WireImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
CULVER CITY, Calif., June 07, 2024--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockholders of record at the close of business on April 17, 2024 are entitled to vote at and participate in the Annual Meeting.
Business WireConnecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
CULVER CITY, Calif., May 17, 2024--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the publication of three podcasts with UroToday highlighting the company’s recent FDA approval of ANKTIVA® (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) and advances in bladder cancer research.
Simply Wall St.ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
ImmunityBio ( NASDAQ:IBRX ) First Quarter 2024 Results Key Financial Results Net loss: US$134.1m (loss widened by 15...
